Executive summary On July 21, 2020, the United States (U.S.) government, Pfizer, and BioNTech signed a contract, known as a Statement of Work (SOW), for the rapid development of and obtaining regulatory licensure for a COVID-19 vaccine by October 31, 2020, a few days prior to the November 3, 2020, […]
Follow-Up to “NAATs Used in Pfizer Clinical Trial to Test Asymptomatic Patients Despite Not Being Approved (or Even Emergency Use Authorized) for Asymptomatic Testing.”
Addendum: Since publication of this piece on April 25, 2023, a new Pfizer document tranche (dated April 3, 2023, but available publicly in late April 2023) has been released, and it included, “Report on Method Validation of a Cepheid Xpert® Xpress PCR Assay to Detect SARS-CoV-2.” The validation report states: “This report […]